Diligence memo · auto-generated · as of July 2, 2026
Portola Pharmaceuticals Inc
Portola Pharmaceuticals Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Portola Pharmaceuticals Inc operates in Pharmaceuticals, based in SOUTH SAN FRANCISCO.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Portola Pharmaceuticals Inc has raised $158M in disclosed capital across 3 recorded rounds, aggregated from public filings. Its latest round is modeled as Series C (a $40M–$100M round).
Largest single filing: $89M on 2011-11-18.
Most recent recorded round closed around 2011-12-07.
Valuation (modeled)modeled
Provath models Portola Pharmaceuticals Inc at approximately $316M (range $29M–$832M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.18× the median modeled value of Series C Pharmaceuticals companies in 2010–2012 (12 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 14.6 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round was 9.9× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 95% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 76% of those peers.
Closest niche peers: Acadia Pharmaceuticals Inc, Agios Pharmaceuticals Inc, Merrimack Pharmaceuticals Inc, PCAS Patient Care Automation Services Inc., China Medicine Corp.
Peoplefiled
16 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.